Kornimate/medical-research-clean huggingface dataset:
identification and validation of a prediction model for cardiovascular events

Conditions: Cardiovascular Diseases

Summary: background: cardiovascular risk stratification is a cornerstone of modern preventive medicine, particularly in patients with multiple comorbidities, where risk estimation is inherently complex. existing tools such as score2 and the cuore project provide important insights into cardiovascular risk but are limited in their ability to account for the interplay of multiple coexisting conditions. objective: the primary aim of this prospective cohort study is to develop and validate a novel cardiovascular risk prediction model specifically tailored for patients with at least two concomitant chronic diseases. secondary objectives include comparing the predictive performance of the new model with that of score2 and the cuore project, and quantifying the incidence of venous thromboembolism (vte), bleeding, and overall mortality in this high-risk population. methods: this is a prospective, monocentric, observational cohort study with an expected duration of 144 months. patients ≥18 years with at least two of a predefined list of chronic conditions will be recruited at the thrombosis unit of fondazione policlinico universitario a. gemelli irccs. clinical, laboratory, and instrumental data will be collected at baseline and during annual follow-up visits, for a maximum follow-up period of 10 years. major cardiovascular events, vte, bleeding, and mortality will be recorded. a fine \& gray competing risks model will be applied for risk modeling, with subsequent validation in an independent cohort. model discrimination and calibration will be evaluated using time-dependent roc curves and calibration plots. expected outcomes: the study aims to generate a robust and clinically applicable cardiovascular risk prediction model that better reflects the complexity of patients with multimorbidity. the model is expected to improve individualized prevention strategies and optimize resource allocation in clinical practice. ethical considerations: the study will be conducted in accordance with the declaration of helsinki and good clinical practice guidelines. informed consent will be obtained from all participants.


Eligibility criteria:
inclusion criteria: * history of at least two of the following conditions: arterial hypertension, dyslipidemia, type 2 diabetes mellitus, ischemic heart disease, heart failure with reduced or preserved ejection fraction, atrial fibrillation, cardiac valvular disease, cerebrovascular disease, obesity, chronic obstructive pulmonary disease, chronic kidney disease, neoplasia (except localized basal cell or squamous cell skin neoplasms), active or previous venous thromboembolism. * age greater than 18 years. * expression of informed consent. exclusion criteria: * unable or unwilling to perform follow-up visits. * life expectancy \< 3 months.

Keywords: cardiovascular diseases venous thromboembolism cancer bleeding risk assessment model
subcutaneous-sublingual immunotherapy with depigmented and polymerized dermatophagoides pteronyssinus allergen extract

Conditions: Allergic Asthma

Summary: the objective of this trial is to evaluate the clinical effectiveness of the administration of a depigmented and polymerized allergen extract dermatophagoides pteronyssinus in children with allergic asthma due to this mite

immunotherapy is a specific treatment for allergic diseases. unlike conventional pharmacological treatment, immunotherapy is the only treatment that could modify the natural course of allergic disease. this is a prospective double-blind placebo controlled study with three arms of treatment: placebo and two active (one of the active arms will receive subcutaneous immunotherapy and the other one will receive sublingual immunotherapy).

Eligibility criteria:
inclusion criteria: * written informed consent signed by the patient and guardian. * positive clinical history of allergy to dust mites. * fev1 greater than or equal to 80% of the expected value and improvement in fev1 greater than 12% after bronchodilation. * age-between 5 and 14 years. * sensitization to dust mites, diagnosed by positive skin tests to dermatophagoides pteronyssinus: wheal size \> 3 mm diameter and / or rast (\> 0.7 ku / l). exclusion criteria: * patients out of the age range. * use of immunotherapy during the last four years. * any contraindication for the use of immunotherapy in accordance with european allergy and clinical immunology immunotherapy subcommittee criteria: * treatment with ß-blockers * patients who have a condition in which adrenaline is contraindicated (hyperthyroidism, hypertension, heart disease, etc..). * coexistence of immunopathological diseases (e.g. of the liver, kidney, the nervous system, thyroid gland, rheumatic diseases) in which autoimmune mechanisms play a role * patients suffering from immune deficiencies * patients with serious psychiatric / psychological disturbances * patients aspirin intolerance

Keywords: immunotherapy allergy allergoid depigmented polymerized allergen-extract mites asthma
a working memory training in burnout patients

Conditions: Burnout

Summary: burnout patients show deficient working memory functioning. several studies showed a training can increase working memory capacity. in the current study we explored whether training working memory can reduce burnout and burnout related symptoms and increase working memory capacity.


Eligibility criteria:
inclusion criteria: * undifferentiated somatoform disorder with a work related cause exclusion criteria: * age which exceeded the range of 18 to 67 years * a severe major depressive episode * substance dependence or abuse

Keywords: burnout working memory working memory training cognitive behavioral therapy executive control
food orders on blood glucose and fuel use at rest

Conditions: Glucose Metabolism Disorders; Hunger; Fat Burn

Summary: consuming a carbohydrate-rich food as the final food in a meal, as compared to the first food in a meal, has been shown to reduce blood glucose levels after eating in both diabetes patients and in healthy controls. however, gaps remain in the literature in this area of research, and currently little is known about how substrate (fuel) use is impacted by altering food order. in addition, most studies to date have used a mix of meat and plant foods, while little research has focused exclusively on vegetarian foods. this randomized experiment will examine how altering the order of foods eaten in a vegetarian meal impacts blood glucose and fuel utilization at rest.


Eligibility criteria:
inclusion criteria: * 18-70 years old * free from any allergy or condition that precluding consumption of edamame, butter, and rice * not currently pregnant * free of any medical conditions requiring the use of insulin * have no history of bariatric surgery * have no implanted electrical devices such as a pacemaker exclusion criteria: * younger than 18 and older than 70 years old * having an allergy or condition that precludes consumption of edamame, butter, and rice * currently pregnant * any medical conditions requiring the use of insulin * a history of bariatric surgery * having an implanted electrical device such as a pacemaker
clinical validation of continuous and non-invasive monitoring of effective pulmonary volume.

Conditions: Critical Illness

Summary: the aim of this study is to evaluate/validate a new non-invasive method to continuously monitor effective lung volume in critically ill patients.

the capnodinamyc method is a new monitoring method that provides continuous (breath by breath) measurements of effective pulmonary blood flow (epbf) and effective end-expiratory l lung volume (eelvco2). the former refers to the non-shunted fraction of cardiac output and the latter to the functional end-expiratory lung volume (eelv) that contains co2. the capnodynamic method is based on the advanced analysis of co2 kinetics and the law of conservation of mass. it states that lungs have to eliminate a similar amounts of co2 as produced by aerobic metabolism and reaches the lung via pulmonary perfusion. for its calculation, two different measurements are needed: 1. exhaled co2 measured by infrared optic sensor technology placed in a mainstream configuration between the endotracheal tube and the "y" piece of the ventilator respiratory circuit. 2. flow, airway pressure and ventilatory volumes measured by the mechanical ventilator spirometer. the method requires the generation of cyclic small changes in the alveolar concentration of co2 which is achieved by introducing a slightly modified breathing pattern. it consists of adding a short expiratory hold in each 3 out of 9 consecutive breaths and requires the patient to be in passive breathing conditions under mechanical ventilation. epbf and eelvco2 have been validated in experimental conditions and the first validations in patients in the setting of general anesthesia are under way. methods: this study on eelvco2 in critically ill patients involves 2 types of evaluations: the validation of absolute values of eelv by comparing it with ctsan. the trending ability of eelvco2 in critically ill patients by comparing it with eit. a calculated sample size of 30 patients is required for each objective.

Eligibility criteria:
inclusion criteria: * all patients on mechanical ventilation in passive breathing conditions in which a thoracic ctscan has been indicated for medical reasons and those with an eit and a continuous cardiac monitoring * informed consent exclusion criteria: * hemodynamic instability * presence of barotrauma/ pneumothorax * presence of bronchopleural fistulas * thorax alterations that preclude the positioning of the eit electrode belt (usually at the iv intercostal space).
outcome of surgical fixation of multiple fractured ribs at sohag university hospital

Conditions: Multiple Fractures of Ribs

Summary: the ribs are rigid and flexible structures that make up the chest skeleton and are a set of twelve paired bones. after blunt trauma rib fractures incidence is about 30 to 40% \[1\]. due to trauma, (4th -9th) ribs are often affected and the fracture point of the ribs is often on the midaxillary line. in ( 1st\&2nd) ribs fractures subclavian vessels and brachial plexus damage may occur. in fractures in the lower ribs (8th-12th ribs), intra-abdominal organs injury such as liver, spleen and kidney should be investigated. 11-12. ribs fractures are rare because the ribs are more flexible (floating). pain is the most important symptom indicating rib fracture, and it usually increases with coughing, breathing, and movement. broken rib ends can be felt with palpation with sever tenderness at the site of fracture. pneumothorax and/or hemothorax may develop as a result of the sharp end of the broken rib causing lung parenchymal damage\[2\].


Eligibility criteria:
inclusion criteria: * multiple fractured ribs pre ventilation exclusion criteria: -
preventing myocardial ischemia by preconditioning in elective operation for abdominal aortic aneurysm

Conditions: Aortic Aneurysm

Summary: primary to investigate whether peripheral predonditioning induced by brief, intermittent constriction of blood supply to an arm can reduce the incidence of perioperative myocardial ischemia in patients operated electively for infrarenal aortic aneurysm. secondary to investigate the impact of peripheral preconditioning on perioperative inflammatory response. to investigate whether peripheral preconditoning can protect against perioperative myocardial infarction and reduced cardiac pump function.


Eligibility criteria:
inclusion criteria: * all patients older than 18 years, hospitalized for elective surgery of abdominal aortic aneurysm exclusion criteria: * lack of informed consent. * hemiparetic patient. * pregnancy or nursing patient.

Keywords: preconditioning aortic aneurysm
evaluation of the toffee nasal and toffee nasal pillows mask in home, usa, 2022

Conditions: Obstructive Sleep Apnea

Summary: this clinical investigation is designed to assess the f\&p toffee nasal and toffee nasal pillows masks in home for use during pap therapy delivery. the objectives of the investigation are to assess therapeutic efficacy, safety and comfort.

this clinical investigation is designed to assess the f\&p toffee nasal and toffee nasal pillows masks in home for use during pap therapy delivery. a target recruitment goal of 45, current pap therapy users per mask type (e.g. nasal and nasal pillows) will be recruited to participate in this investigation to achieve a total sample of 90. the investigation will involve participation in a two week in home trial of the f\&p toffee nasal or toffee nasal pillows mask. the objectives of the investigation are to assess therapeutic efficacy, safety and comfort.

Eligibility criteria:
inclusion criteria: 1. persons who are ≥ 22 years of age 2. persons who weigh ≥ 66 lbs (30 kgs) 3. persons who have been prescribed pap (apap, bpap or cpap) therapy by a physician 4. persons who are compliant with pap therapy for ≥ 4 hours per night for 70% of nights for at least two weeks prior to enrolment in the trial 5. persons who are currently using either a nasal, sub-nasal or nasal pillows mask 6. persons who have an ipap pressure of \< 20 cmh2o 7. persons who currently use a pap therapy device with data recording capabilities 8. persons who are fluent in spoken and written english 9. persons who possess the capacity to provide informed consent exclusion criteria: 1. persons who are intolerant to pap therapy 2. persons who are required to use pap therapy for more than 12 hours per day or for extensive periods other than sleep or naps 3. persons using full face masks 4. persons who possess, or suffer from, anatomical or physiological conditions which make pap therapy inappropriate 5. persons who are pregnant or think they may be pregnant 6. persons who use a pap therapy machine for the delivery of medicines, except supplemental o2

Keywords: positive airway pressure therapy
clinical study of excimer laser and drug coated balloon versus excimer laser and plain balloon versus plain balloon and drug coated balloon to treat femoropopliteal in-stent restenosis

Conditions: Atherosclerosis of Artery; In-stent Arterial Restenosis

Summary: this is a randomized study comparing excimer laser and drug coated balloon versus excimer laser and plain balloon versus plain balloon and drug coated balloon to treat femoropopliteal in-stent restenosis

this is a randomized study comparing excimer laser and drug coated balloon versus excimer laser and plain balloon versus plain balloon and drug coated balloon to treat femoropopliteal in-stent restenosis

Eligibility criteria:
inclusion criteria: provides written informed consent willing to comply with follow-up evaluations at specified times has claudication or rest pain due to peripheral arterial in-stent restenosis disease located within the femoropopliteal artery patient has a in-stent restenosis lesion(s) with \>50% stenosis documented angiographically patient has symptoms of peripheral arterial disease classified as rutherford category 2 or greater. exclusion criteria: they were excluded if they had one or more of the following: 1. acute or subacute lower limb ischemia; 2. severe calcification lesions; 3. total occlusions lesions more significant than 10 cm or total occlusion lesions with a suspicion of subintimal wire recanalization 4. untreated ipsilateral iliac artery stenosis\>70%, or the distal runoff artery \<1 root; 5. previously lower extremity intervention or surgical graft artery bypass; 6. severe renal insufficiency, creatinine level greater than 2.5 mg/dl; 7. the patient's platelet count is less than 100,000/ul, antiplatelet or anticoagulant contraindications to required medications; 8. patients with immune system diseases or malignant tumours; 9. ongoing active infection 10. decompensated congestive heart failure or acute coronary syndrome; 11. unwillingness to return for future follow-up visits

Keywords: excimer laser drug coated balloon femoropopliteal in-stent restenosis
comparison of doxycycline and common salt for treatment of umbilical granuloma: a randomised control trial

Conditions: Umbilical Granuloma

Summary: it is the study for the disease called umbilical granuloma to look for the better treatment option which can be performed by healthcare physicians and local nurses and even parents

umbilical granuloma is a condition for which multiple treatments are available those including interventional and non interventional, most of the treatments are performed by the health care physician like application of silver nitrate cryotherapy, electrocautery, double ligation. the main goal of this study is to prefer those method or drugs which could be safely used by the nurses the health care personal and even by parents at home with fewer side effects

Eligibility criteria:
inclusion criteria: * inclusion criteria: 1. neonates and infants (age\<1yr) 2. both genders 3. confirmed by ultrasonography and sinography (if applicable) exclusion criteria: * 1. if any treatment is already given 2. patient lost in follow up 3. refusal
a new method: the third space robotic and endoscopic cooperative surgery (ts-recs)

Conditions: Gastric Soft Tissue Neoplasm

Summary: the third space robotic and endoscopic cooperative surgery (ts-recs) combines the endoscopic techniques and the merits of da vinci surgical robot, such as flexible and precise instruments, tremors filtering system and a 3-d surgical view. ts-recs takes full advantage of the methodology of the third space, making it possible to dissect gastric gists (gastrointestinal stromal tumors) entirely without the damage of mucosal layer. here, this study preliminarily assessed the feasibility, safety and effectivity of the novel hybrid operation.


Eligibility criteria:
inclusion criteria: * patients with gastric gists originating from muscularis propria diagnosed by eus (endoscopic ultrasound)； * the maximal cross-sectional diameter of tumor ranging from 2cm to 5cm, or the maximal cross-sectional diameter of tumor \<2cm but with malignant potential ( irregular shape, cystic space, heterogeneity and rapid growth during follow-ups ) ； * no evidence of tumor metastasis on all per-operative evaluations； exclusion criteria: * 1. patients with serious systemic comorbidities, such as severe heart failure, respiratory failure, uncontrolled hypertension; * 2. patients with advanced malignant tumor; * 3. patients were required the emergency operation by complete intestinal obstruction, perforation and hemorrhage caused by the tumor; * 4.patients with ulcer penetration into tumors; * 5. patients with the contraindications for general anesthesia; * 6. patients were pregnant or younger than 18 years old；
fuzzy wale compression stockinet to promote healing following transtibial amputation for peripheral arterial disease

Conditions: Peripheral Arterial Disease

Summary: the objective of this study is to determine if using fuzzy wale compression stockinett can assist in reducing the healing time and decrease costs in trastibial amputation patients as compared to standard of care treatment compression stocking.


Eligibility criteria:
inclusion criteria: * \>18 years * male and female * transtibial amputation expected. * peripheral arterial disease and transcutaneous partial pressure of oxygen (tcp02, if performed) * ability of subject to give appropriate consent or have an appropriate representative available to do so. exclusion criteria: * known allergies to any of the components of the compression. * terminal illness or current cancer therapy with chemotherapy * inability to undergo ongoing care in rochester. * lack of cognitive ability to follow instructions or monitor residual limb. * vulnerable study population * pregnancy
immunogenicity and safety of 2 schedules of alvac-hiv vcp1452 in chronically hiv-infected patients

Conditions: HIV Infection

Summary: prior pilot studies have shown that four monthly injections of alvac-hiv (vcp1433) are immunogenic in 60% hiv-infected patients with a boosting effect obtained after 1 or 2 injections followed by a plateau or a decrease of these responses prior to interrupting therapy. the goal of the present study is to look for an improved vaccination schedule in terms of strength and duration of the hiv-specific immunity induced by the hiv-recombinant canary pox vector alvac-hiv (vcp1452) by testing a strategy of immunization involving a first series of two versus three monthly injections followed by a boost three months later.

manon 02 is a phase ii, multicentre, randomized, placebo-controlled study with 3 arms comprising 2 steps: step i : immunization phase from w0 to w24, on haart the immunization will be administered by intramuscular injection : arm a: one injection of vcp1452 at w0, w4, w8 and w20 + haart, for a total of 4 injections arm b: one injection of vcp1452 at w4, w8 and w20 + haart, for a total of 3 injections arm c: one injection of placebo at w0, w4, w8 and w20 + haart, for a total of 4 injections or at w4, w8 and w20 + haart, for a total of 3 injections step ii: post immunization phase from w24 to w48, off haart discontinuation of antiretroviral therapy (arv) from w24 to w48 : the arv treatment interruption will be proposed at w24, 4 weeks after the last immunization, to patient who had completed their immunization phase and have cd4 cell counts \> 350 cells/mm3 and hiv plasma rna \< 400 cp/ml. in order to be able to evaluate the capacity of the immune response to reduce the viral replication, a period of 16 weeks of interruption is recommended from w24 to w40. resumption of antiretroviral therapy : from w24 to w40 : during this 16 weeks period, in case of a decline of cd4 cell counts below 250 cells/mm3 or of a loss of cd4 greater than 50% of the baseline value, haart will be restarted. from w40 to w48 : haart should be reintroduced if hiv-1 rna levels \> 50 000 cp/ml on 2 consecutive measurements at two weeks interval even if the cd4 counts are above 250 cells/mm3.

Eligibility criteria:
inclusion criteria: * documented hiv infection * under potent antiretroviral therapy for more than 6 months * with entry cd4+ counts \> 350 cells/mm3 for at least 1 year * plasma hiv rna \< 400 cp/ml for at least the last 6 months * contraception needed for women exclusion criteria: * antiretroviral therapy started with cd4 cell count \> 400/mm3 * patients treated at time of primary hiv infection * patient with past aids defining event

Keywords: hiv-1 infection therapeutic vaccine treatment experienced